A study of dynamic strategic planning model for oversea plants

학위논문(석사) - 한국과학기술원 : 테크노경영대학원, 1997.2, [ vi, 132 p. ]한국과학기술원 : 테크노경영대학원

Comparison of Clinical Outcome between Nafarelin and Triptorelin in Controlled Ovarian Hyperstimulation for In Vitro Fertilization: A Randomized Clinical Trial

Gonadotropin-releasing hormone agonists(GnRH-a) vary in structure and route of administration. We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous triptorelin as adjuncts to ovulation induction for in vitro fertilization(IVF). From October 1995 to May 1996, sixty-four patients with tubal factor infertility entering their 79 cycles of IVF were randomized to receive either intranasal nafarelin acetate(Group Ⅰ, 38 cycles) or subcutaneous triptorelin(Group Ⅱ, 41 cycles). Controlled ovarian hyperstimulation(COH) using luteal long protocol of GnRH-a was used in all patients. Patient characteristics in the two groups did not differ significantly, nor did sperm parameters or endocrine profiles. There was no significant difference in ovarian response as indicated by duration of GnRH-a administration before ovarian stimulation, number of ampules of gonadotropin used and duration of gonadotropin administration in ovarian stimulation, and serum E( ) level and number of follicles(≥14mm) on the day of hCG administration between the two groups. There were no significant differences in clinical results of oocyte and embryo obtained such as number of oocytes retrieved, oocytes fertilized, embryos cleaved, embryos frozen, and embryos transfered between the two groups. There were also no significant differences between group Ⅰ and group Ⅱ in clinical pregnancy rate(31.6% versus 34.1%) and abortion rate per clinical pregnancy(8.3% versus 14.3%). This study suggests that intranasal nafarelin acetate as well as subcutaneous triptorelin can be used successfully in ovulation induction using luteal long protocol of GnRH-a.Gonadotropin-releasing hormone agonists(GnRH-a) vary in structure and route of administration. We performed this study to compare patient response to intranasal nafarelin acetate versus subcutaneous triptorelin as adjuncts to ovulation induction for in vitro fertilization(IVF). From October 1995 to May 1996, sixty-four patients with tubal factor infertility entering their 79 cycles of IVF were randomized to receive either intranasal nafarelin acetate(Group Ⅰ, 38 cycles) or subcutaneous triptorelin(Group Ⅱ, 41 cycles). Controlled ovarian hyperstimulation(COH) using luteal long protocol of GnRH-a was used in all patients. Patient characteristics in the two groups did not differ significantly, nor did sperm parameters or endocrine profiles. There was no significant difference in ovarian response as indicated by duration of GnRH-a administration before ovarian stimulation, number of ampules of gonadotropin used and duration of gonadotropin administration in ovarian stimulation, and serum E( ) level and number of follicles(≥14mm) on the day of hCG administration between the two groups. There were no significant differences in clinical results of oocyte and embryo obtained such as number of oocytes retrieved, oocytes fertilized, embryos cleaved, embryos frozen, and embryos transfered between the two groups. There were also no significant differences between group Ⅰ and group Ⅱ in clinical pregnancy rate(31.6% versus 34.1%) and abortion rate per clinical pregnancy(8.3% versus 14.3%). This study suggests that intranasal nafarelin acetate as well as subcutaneous triptorelin can be used successfully in ovulation induction using luteal long protocol of GnRH-a

Congenital Obstructive Mullerian Anomaly: The Pitfalls of a Magnetic Resonance Imaging-Based Diagnosis and the Importance of Intraoperative Biopsy

A retrospective cohort study of the concordance between the magnetic resonance imaging (MRI) diagnosis and final diagnosis in patients with Mullerian duct anomalies (MDAs) was conducted, and diagnostic clues were suggested. A total of 463 cases of young women who underwent pelvic MRIs from January 1995 to February 2019 at Seoul Asan Medical Center were reviewed. Interventions consisted of clinical examinations, abdominal or transvaginal/rectal ultrasound, MRI, and operative procedures, including hysteroscopy and laparoscopy. The concordance of the diagnosis between the results obtained with MRI and those obtained with surgeries was evaluated. It was found that a total of 225 cases (48.6%) showed genital tract anomalies on MRI. Among them, 105 cases (46.7%) underwent reconstructive surgery. Nineteen cases (8.4%) revealed discrepancies between the final diagnosis after surgery and the initial MRI findings and eleven cases (57.9%) had cervical anomalies. Incorrect findings associated with the MRIs were particularly evident in biopsied cases of cervical dysgenesis. A combination of physical examination, ultrasound, and MRI is suitable for preoperative work-up in the diagnoses of congenital obstructive anomalies. However, it is recommended that a pathologic confirmation of tissue at the caudal leading edge be made in obstructive genital anomalies, in cases of presumptive vaginal or cervical dysgenesis